Pravachol/Aspirin Fixed-Dose Inflexibility May Lead To Undertreatment
Executive Summary
Bristol-Myers Squibb's Pravachol/Bufferin titration inflexibility was cited as a main issue by FDA's Cardiovascular & Renal Drugs Advisory Committee in voting against approval of the fixed-dose combination of the cholesterol-lowering and aspirin products